{"id":"nrl-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL524","moleculeType":"Small molecule","molecularWeight":"211.26"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NRL-1 acts as a positive allosteric modulator of GABA-A receptors, increasing the frequency and duration of chloride channel opening to enhance inhibitory signaling. This mechanism is intended to provide rapid seizure control and potentially address other conditions involving excessive neuronal excitability.","oneSentence":"NRL-1 is a neuroactive steroid that enhances GABAergic inhibitory neurotransmission in the central nervous system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:26.211Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute repetitive seizures (clusters)"},{"name":"Status epilepticus"}]},"trialDetails":[{"nctId":"NCT02721069","phase":"PHASE3","title":"Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects","status":"COMPLETED","sponsor":"Neurelis, Inc.","startDate":"2016-04-11","conditions":"Acute Repetitive Seizures, Breakthrough Seizures","enrollment":175},{"nctId":"NCT02724423","phase":"PHASE1","title":"Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects","status":"COMPLETED","sponsor":"Neurelis, Inc.","startDate":"2016-06-30","conditions":"Acute Repetitive Seizures","enrollment":57}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Intranasal diazepam"],"phase":"phase_3","status":"active","brandName":"NRL-1","genericName":"NRL-1","companyName":"Neurelis, Inc.","companyId":"neurelis-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NRL-1 is a neuroactive steroid that enhances GABAergic inhibitory neurotransmission in the central nervous system. Used for Acute repetitive seizures (clusters), Status epilepticus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}